J
Johanna Mattson
Researcher at University of Helsinki
Publications - 48
Citations - 1431
Johanna Mattson is an academic researcher from University of Helsinki. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 10, co-authored 28 publications receiving 1071 citations.
Papers
More filters
Journal ArticleDOI
RAD51B in Familial Breast Cancer
Liisa M. Pelttari,Sofia Khan,Mikko Vuorela,Johanna I. Kiiski,Sara Vilske,Viivi Nevanlinna,Salla Ranta,Johanna Schleutker,Johanna Schleutker,Johanna Schleutker,Robert Winqvist,Anne Kallioniemi,Thilo Dörk,Natalia Bogdanova,Jonine Figueroa,Paul D.P. Pharoah,Marjanka K. Schmidt,Alison M. Dunning,Montserrat Garcia-Closas,Manjeet K. Bolla,Joe Dennis,Kyriaki Michailidou,Qin Wang,John L. Hopper,Melissa C. Southey,Efraim H. Rosenberg,Peter A. Fasching,Peter A. Fasching,Matthias W. Beckmann,Julian Peto,Isabel dos-Santos-Silva,Elinor J. Sawyer,Ian Tomlinson,Barbara Burwinkel,Barbara Burwinkel,Harald Surowy,Harald Surowy,Pascal Guénel,Thérèse Truong,Stig E. Bojesen,Stig E. Bojesen,Børge G. Nordestgaard,Børge G. Nordestgaard,Javier Benitez,Anna González-Neira,Susan L. Neuhausen,Hoda Anton-Culver,Hermann Brenner,Volker Arndt,Alfons Meindl,Rita K. Schmutzler,Hiltrud Brauch,Hiltrud Brauch,Hiltrud Brauch,Thomas Brüning,Annika Lindblom,Sara Margolin,Arto Mannermaa,Jaana M. Hartikainen,Georgia Chenevix-Trench,kConFab,kConFab,Aocs Investigators,Laurien Van Dyck,Hilde Janssen,Hilde Janssen,Jenny Chang-Claude,Anja Rudolph,Paolo Radice,Paolo Peterlongo,Emily Hallberg,Janet E. Olson,Janet E. Olson,Graham G. Giles,Graham G. Giles,Roger L. Milne,Christopher A. Haiman,Fredrick Schumacher,Jacques Simard,Martine Dumont,Martine Dumont,Vessela N. Kristensen,Vessela N. Kristensen,Anne Lise Børresen-Dale,Wei Zheng,Alicia Beeghly-Fadiel,Mervi Grip,Mervi Grip,Irene L. Andrulis,Gord Glendon,Peter Devilee,Caroline Seynaeve,Maartje J. Hooning,Margriet Collée,Angela Cox,Simon S. Cross,Mitul Shah,Robert Luben,Ute Hamann,Ute Hamann,Diana Torres,Anna Jakubowska,Jan Lubinski,Fergus J. Couch,Drakoulis Yannoukakos,Nick Orr,Anthony J. Swerdlow,Hatef Darabi,Jingmei Li,Kamila Czene,Per Hall,Douglas F. Easton,Johanna Mattson,Carl Blomqvist,Kristiina Aittomäki,Heli Nevanlinna +115 more
TL;DR: It is suggested that loss-of-function mutations in RAD 51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.
Journal ArticleDOI
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura,Mafalda Oliveira,Yin-Hsun Feng,Ming-Shen Dai,Shang Wen Chen,Sara A. Hurvitz,Sung Bae Kim,Beverly Moy,Suzette Delaloge,William J. Gradishar,Norikazu Masuda,Marketa Palacova,Maureen E. Trudeau,Johanna Mattson,Yoon Sim Yap,Ming-Feng Hou,Michelino De Laurentiis,Yu-Min Yeh,Hong-Tai Chang,Thomas Yau,Hans Wildiers,Barbara Haley,Daniele Fagnani,Yen-Shen Lu,John Crown,Johnson Lin,Masato Takahashi,Toshimi Takano,Miki Yamaguchi,Takaaki Fujii,Bin Yao,Judith Bebchuk,Kiana Keyvanjah,Richard Bryce,Adam Brufsky,Nala Investigators +35 more
TL;DR: N+C significantly improved PFS and time to intervention for CNS disease versus L+C and no new N+C safety signals were observed.
Journal ArticleDOI
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
Cristina Saura,Mafalda Oliveira,Yin-Hsun Feng,Ming-Shen Dai,Sara A. Hurvitz,Sung-Bae Kim,Beverly Moy,Suzette Delaloge,William J. Gradishar,Norikazu Masuda,Markéta Palácová,Maureen E. Trudeau,Johanna Mattson,Yoon Sim Yap,Richard A. Bryce,Bin Yao,Judith Bebchuk,Kiana Keyvanjah,Adam Brufsky +18 more
TL;DR: NALA (ClinicalTrials.gov NCT01808573) is a multinational, randomized, open-label, phase III trial of neratinib (an irreversible pan-HER tyrosine kinase inhibitor [TKI] + capecitabi...
Journal ArticleDOI
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Heidi M. Haikala,Heidi M. Haikala,Johanna M. Anttila,Elsa Marques,Tiina Raatikainen,Mette Ilander,Henna Hakanen,Hanna Ala-Hongisto,Mariel Savelius,Diego Balboa,Bjoern von Eyss,Vilja Eskelinen,Pauliina Munne,Anni I. Nieminen,Timo Otonkoski,Julia Schüler,Teemu D. Laajala,Teemu D. Laajala,Tero Aittokallio,Tero Aittokallio,Harri Sihto,Johanna Mattson,Päivi Heikkilä,Marjut Leidenius,Heikki Joensuu,Satu Mustjoki,Panu E. Kovanen,Martin Eilers,Joel D. Leverson,Juha Klefström +29 more
TL;DR: It is demonstrated that AMPK activation and BCL-2/BCL-XL inhibition have a synergistic effect on apoptosis, and that together with anti PD-1 therapy they can suppress Myc-driven mammary tumor growth.
Journal ArticleDOI
Resection margins and local recurrences in breast cancer: Comparison between conventional and oncoplastic breast conserving surgery.
Laura Niinikoski,Marjut Leidenius,Päivi Vaara,Aleksandar Voynov,Päivi Heikkilä,Johanna Mattson,Tuomo J. Meretoja +6 more
TL;DR: Oncoplastic BCS is as safe as conventional BCS enabling breast conserving for patients who otherwise were candidates for mastectomy, and no difference in reoperation rate or local recurrences were found.